Jan Cosaert
AstraZeneca Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.
Journal: British journal of cancer
Published: July 14, 2025
Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.
Journal: JTO clinical and research reports
Published: April 28, 2025
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
Journal: British journal of cancer
Published: February 29, 2024
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Journal: British journal of cancer
Published: June 17, 2022
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Journal: Nature medicine
Published: May 29, 2020
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Journal: Oral oncology
Published: March 24, 2018
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 16, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: December 19, 2016
Last Updated: 09/26/2026